3rd TIGIT Axis Therapies Summit
The 3rd TIGIT Axis Therapies Summit returns to unite large pharma, innovative biotechs and pioneering academics to discuss the full range of next-generation TIGIT axis targeted […]
TIGIT
GSK, iTeos take stock after Roche’s TIGIT setback
iTeos Therapeutics has said it is evaluating with partner GlaxoSmithKline whether to conduct additional clinical trials of TIGIT drug EOS-448 following the failure of a […]
Roche’s TIGIT ambitions take another blow
Roche’s anti-TIGIT antibody tiragolumab has failed a second phase 3 trial, dousing expectations for the programme and its hopes of finding a companion to its […]
Roche hit by failure of TIGIT drug tiragolumab in lung cancer
Roche has suffered a setback with its much-anticipated pairing of anti-TIGIT antibody tiragolumab and PD-L1 inhibitor Tecentriq in small cell lung cancer (SCLC), in a […]
Novartis taps immuno-oncology partner BeiGene for TIGIT drug
Novartis has joined the ranks of big pharma companies developing TIGIT-targeted drugs for cancer, and found its candidate in an existing partner, Chinese biotech BeiGene. […]
Roche builds case for TIGIT combo in untreated lung cancer
Roche’s closely-watched combination of anti-TIGIT antibody tiragolumab and PD-L1 inhibitor Tecentriq has shown long-term efficacy in an ongoing trial in lung cancer, adding to the […]
Gilead foregoes buyout, but pledges $725m to Arcus’ cancer drugs
Gilead Sciences has forged closer ties to its cancer drug partner Arcus Biosciences , although a licensing deal doesn’t go as far as the takeover […]
TIGIT Therapies 2021
Arriving at a critical point for TIGIT development, the 2nd Annual TIGIT Therapies Summit is the definitive industry-led event focused on propelling this next-generation inhibitor […]
GSK joins ant-TIGIT push with $625m upfront iTeos deal
GlaxoSmithKline has staked a claim to the fast-moving category of cancer therapies targeting the TIGIT immune checkpoint, agreeing a $2 billion plus licensing agreement with […]
BMS agrees deal worth up to $1.56bn for Agenus’ TIGIT cancer drug
Bristol-Myers Squibb has paid $200 million, and promised up to $1.36 billion in “biobucks” for exclusive rights to a cancer antibody still in the labs […]
Roche nabs breakthrough tag for TIGIT cancer immunotherapy
Roche’s closely-watched combination of two checkpoint inhibitors – TIGIT-targeting tiragolumab and PD-L1 drug Tecentriq – has claimed breakthrough status from the FDA. Like PD-L1, TIGIT […]
TIGIT Therapies Digital Summit
The TIGIT checkpoint has gained much attention in recent years due to the number of roles it plays in several malignancies. TIGIT’s diverse function in multiple cell […]
